차이니즈 햄스터 난소 세포 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of Chinese hamster ovary cell Market

The global Chinese hamster ovary cell market size was valued at USD 5.78 billion in 2025. The market is projected to grow from USD 6.36 billion in 2026 to USD 14.13 billion by 2034, exhibiting a CAGR of 10.50% during the forecast period. North America dominated the global market with a 43.77% share in 2025, valued at approximately USD 2.53 billion. Chinese Hamster Ovary (CHO) cells are widely used in biopharmaceutical manufacturing, particularly for monoclonal antibodies and recombinant therapeutic proteins. Growing biologics pipelines, biosimilar development, outsourcing to CROs and CDMOs, and recurring demand for CHO media, feeds, supplements, and expression systems are supporting market growth.

CHO-based platforms enable pharmaceutical and biotechnology companies to develop stable cell lines and manufacture complex therapeutic proteins at commercial scale. The market includes CHO cell lines, culture media, expression systems, vectors, selection systems, feeds, supplements, cell-line development services, and process-development support. Increasing investments in advanced expression technologies are also encouraging suppliers to offer integrated CHO platforms rather than individual products.

Market Definition and Scope

The Chinese hamster ovary cell market comprises products and services used for CHO-based cell-line development, biologics research, process optimization, and clinical or commercial bioproduction. The market is segmented by offering, workflow, application, and end user. Applications include monoclonal antibody production, recombinant protein production, biosimilar development, toxicology, and basic research.

The market serves pharmaceutical and biotechnology companies, CROs and CDMOs, research institutions, and academic organizations. Increasing demand for stable, scalable, and high-productivity cell lines is expanding the use of CHO platforms across the biologics development lifecycle.

Market Dynamics

Drivers

The growing monoclonal antibody and recombinant biologics pipeline is a major driver of market expansion. CHO cells are extensively used for antibody expression, stable cell-line development, process optimization, and large-scale manufacturing. The increasing development of biosimilars and biologics following patent expiries is also creating recurring demand for CHO-based technologies and services.

Trends

A significant trend is the shift toward integrated CHO expression platforms combining host cells, vectors, selection systems, optimized media, feeds, and process-development support. Such platforms aim to reduce clone-screening time, improve expression stability, increase productivity, and accelerate biologics development. In September 2025, WuXi Biologics launched its TrueSite TI fourth-generation targeted-integration CHO cell-line platform.

Restraints

High costs and long timelines associated with CHO cell-line development, clone screening, process optimization, and scale-up remain key restraints. Complex regulatory and quality requirements further increase development costs. Competition from HEK293, microbial, yeast, and insect-cell expression systems can also limit CHO adoption for certain applications.

Opportunities and Challenges

Growing outsourcing to CROs and CDMOs creates significant opportunities, particularly for small and mid-sized biotechnology companies lacking internal CHO capabilities. Integrated services covering cell-line development, GMP scale-up, cell banking, and manufacturing can improve development efficiency. However, alternative expression systems remain a challenge because some molecules may be produced more efficiently using other platforms.

Impact of COVID-19

The COVID-19 pandemic created disruptions across biopharmaceutical research, manufacturing, supply chains, and laboratory operations. However, the importance of biologics manufacturing and therapeutic development supported continued investment in cell-based production technologies. As pharmaceutical development activities normalized, demand for CHO-based biologics development and manufacturing infrastructure increased.

Segmentation Analysis

By offering, products dominated the market in 2025, supported by recurring consumption of CHO media, feeds, cell lines, expression systems, and development kits. The services segment is projected to grow at a CAGR of 11.83% through 2034.

By workflow, commercial/clinical bioproduction support dominated in 2025 and is expected to hold a 29.5% share in 2026. Process development and scale-up is projected to grow at a CAGR of 11.73%.

By application, monoclonal antibody production dominated in 2025, with the segment expected to hold a 46.5% share in 2026. Biosimilar development is projected to grow at a CAGR of 15.50%.

By end user, pharmaceutical and biotechnology companies dominated in 2025 and are expected to hold a 52.9% share in 2026. CROs/CDMOs are projected to grow at a CAGR of 13.35%.

Regional Insights

North America dominated the global market with USD 2.53 billion in 2025, supported by a strong biologics pipeline, major pharmaceutical and biotechnology companies, advanced CHO technologies, and increasing biosimilar activity. The U.S. market is estimated at USD 2.49 billion in 2026.

Asia Pacific is expected to be the fastest-growing regional market and is projected to reach USD 1.40 billion in 2026. China, Japan, and India are estimated at USD 0.53 billion, USD 0.36 billion, and USD 0.19 billion, respectively, in 2026. Europe is projected to grow at a 9.72% CAGR, supported by its mature biosimilar ecosystem and established biologics manufacturing base.

Competitive Landscape

Key companies include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Sartorius AG, Lonza, American Type Culture Collection, FUJIFILM Corporation, WuXi Biologics, AGC Biologics, and Charles River Laboratories. Companies are focusing on high-productivity CHO cell lines, integrated expression platforms, optimized media and feeds, targeted integration, and outsourced cell-line development services.

Report Coverage

The report covers the global Chinese hamster ovary cell market size and forecast for 2025, 2026, and 2034, along with market dynamics, trends, drivers, restraints, opportunities, challenges, segmentation by offering, workflow, application, and end user, regional analysis, competitive landscape, key industry developments, and company profiles.

Conclusion

The global Chinese hamster ovary cell market is projected to expand from USD 5.78 billion in 2025 to USD 6.36 billion in 2026 and USD 14.13 billion by 2034, registering a 10.50% CAGR. Rising monoclonal antibody development, biosimilar pipelines, biologics manufacturing, CRO/CDMO outsourcing, and integrated CHO expression platforms are expected to support sustained market expansion. North America remained the leading regional market in 2025, while Asia Pacific is expected to experience strong growth through 2034. Continued innovation in high-productivity cell lines, media, feeds, and development services is expected to remain important to the market.

Segmentation By Offering, Workflow, Application, End User, and Region

By Offering

• Products
  • CHO Cell Lines
  • Cell Culture Media
  • Expression Systems & Cell Line Development Kits
  • Vectors & Selection Systems
  • Feeds & Supplements
  • Others
• Services

By Workflow

• Transient Expression
• Stable Cell Line Development
• Process Development & Scale-up
• Commercial/Clinical Bioproduction Support
• Others

By Application

• MAb Production
• Recombinant Protein Production
• Biosimilar Development
• Toxicology & Basic Research
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• CROs/CDMOs
• Academic & Research Institutes
• Others

By Region

• North America (By Offering, Workflow, Application, End User, and Country)
  • U.S.
  • Canada
• Europe (By Offering, Workflow, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Offering, Workflow, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Offering, Workflow, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Offering, Workflow, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Technological Advancements in CHO Cell Lines
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Regulatory Guidelines in CHO Cell Development

5. Global Chinese Hamster Ovary Cell Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Offering
  • 5.1.1. Products
    • 5.1.1.1. CHO Cell Lines
    • 5.1.1.2. Cell Culture Media
    • 5.1.1.3. Expression Systems & Cell Line Development Kits
    • 5.1.1.4. Vectors & Selection Systems
    • 5.1.1.5. Feeds & Supplements
    • 5.1.1.6. Others
  • 5.1.2. Services
• 5.2. Market Analysis, Insights and Forecast - By Workflow
  • 5.2.1. Transient Expression
  • 5.2.2. Stable Cell Line Development
  • 5.2.3. Process Development & Scale-up
  • 5.2.4. Commercial / Clinical Bioproduction Support
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. MAb Production
  • 5.3.2. Recombinant Protein Production
  • 5.3.3. Biosimilar Development
  • 5.3.4. Toxicology & Basic Research
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical & Biotechnology Companies
  • 5.4.2. CROs/CDMOs
  • 5.4.3. Academic & Research Institutes
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Chinese Hamster Ovary Cell Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Offering
  • 6.1.1. Products
    • 6.1.1.1. CHO Cell Lines
    • 6.1.1.2. Cell Culture Media
    • 6.1.1.3. Expression Systems & Cell Line Development Kits
    • 6.1.1.4. Vectors & Selection Systems
    • 6.1.1.5. Feeds & Supplements
    • 6.1.1.6. Others
  • 6.1.2. Services
• 6.2. Market Analysis, Insights and Forecast - By Workflow
  • 6.2.1. Transient Expression
  • 6.2.2. Stable Cell Line Development
  • 6.2.3. Process Development & Scale-up
  • 6.2.4. Commercial / Clinical Bioproduction Support
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. MAb Production
  • 6.3.2. Recombinant Protein Production
  • 6.3.3. Biosimilar Development
  • 6.3.4. Toxicology & Basic Research
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical & Biotechnology Companies
  • 6.4.2. CROs/CDMOs
  • 6.4.3. Academic & Research Institutes
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Chinese Hamster Ovary Cell Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Offering
  • 7.1.1. Products
    • 7.1.1.1. CHO Cell Lines
    • 7.1.1.2. Cell Culture Media
    • 7.1.1.3. Expression Systems & Cell Line Development Kits
    • 7.1.1.4. Vectors & Selection Systems
    • 7.1.1.5. Feeds & Supplements
    • 7.1.1.6. Others
  • 7.1.2. Services
• 7.2. Market Analysis, Insights and Forecast - By Workflow
  • 7.2.1. Transient Expression
  • 7.2.2. Stable Cell Line Development
  • 7.2.3. Process Development & Scale-up
  • 7.2.4. Commercial / Clinical Bioproduction Support
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. MAb Production
  • 7.3.2. Recombinant Protein Production
  • 7.3.3. Biosimilar Development
  • 7.3.4. Toxicology & Basic Research
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical & Biotechnology Companies
  • 7.4.2. CROs/CDMOs
  • 7.4.3. Academic & Research Institutes
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Chinese Hamster Ovary Cell Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Offering
  • 8.1.1. Products
    • 8.1.1.1. CHO Cell Lines
    • 8.1.1.2. Cell Culture Media
    • 8.1.1.3. Expression Systems & Cell Line Development Kits
    • 8.1.1.4. Vectors & Selection Systems
    • 8.1.1.5. Feeds & Supplements
    • 8.1.1.6. Others
  • 8.1.2. Services
• 8.2. Market Analysis, Insights and Forecast - By Workflow
  • 8.2.1. Transient Expression
  • 8.2.2. Stable Cell Line Development
  • 8.2.3. Process Development & Scale-up
  • 8.2.4. Commercial / Clinical Bioproduction Support
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. MAb Production
  • 8.3.2. Recombinant Protein Production
  • 8.3.3. Biosimilar Development
  • 8.3.4. Toxicology & Basic Research
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical & Biotechnology Companies
  • 8.4.2. CROs/CDMOs
  • 8.4.3. Academic & Research Institutes
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Chinese Hamster Ovary Cell Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Offering
  • 9.1.1. Products
    • 9.1.1.1. CHO Cell Lines
    • 9.1.1.2. Cell Culture Media
    • 9.1.1.3. Expression Systems & Cell Line Development Kits
    • 9.1.1.4. Vectors & Selection Systems
    • 9.1.1.5. Feeds & Supplements
    • 9.1.1.6. Others
  • 9.1.2. Services
• 9.2. Market Analysis, Insights and Forecast - By Workflow
  • 9.2.1. Transient Expression
  • 9.2.2. Stable Cell Line Development
  • 9.2.3. Process Development & Scale-up
  • 9.2.4. Commercial / Clinical Bioproduction Support
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. MAb Production
  • 9.3.2. Recombinant Protein Production
  • 9.3.3. Biosimilar Development
  • 9.3.4. Toxicology & Basic Research
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical & Biotechnology Companies
  • 9.4.2. CROs/CDMOs
  • 9.4.3. Academic & Research Institutes
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Chinese Hamster Ovary Cell Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Offering
  • 10.1.1. Products
    • 10.1.1.1. CHO Cell Lines
    • 10.1.1.2. Cell Culture Media
    • 10.1.1.3. Expression Systems & Cell Line Development Kits
    • 10.1.1.4. Vectors & Selection Systems
    • 10.1.1.5. Feeds & Supplements
    • 10.1.1.6. Others
  • 10.1.2. Services
• 10.2. Market Analysis, Insights and Forecast - By Workflow
  • 10.2.1. Transient Expression
  • 10.2.2. Stable Cell Line Development
  • 10.2.3. Process Development & Scale-up
  • 10.2.4. Commercial / Clinical Bioproduction Support
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. MAb Production
  • 10.3.2. Recombinant Protein Production
  • 10.3.3. Biosimilar Development
  • 10.3.4. Toxicology & Basic Research
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical & Biotechnology Companies
  • 10.4.2. CROs/CDMOs
  • 10.4.3. Academic & Research Institutes
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Thermo Fisher Scientific Inc.
  • 11.2.2. Merck KGaA
  • 11.2.3. Danaher Corporation
  • 11.2.4. Sartorius AG
  • 11.2.5. Lonza
  • 11.2.6. American Type Culture Collection
  • 11.2.7. FUJIFILM Corporation
  • 11.2.8. WuXi Biologics.
  • 11.2.9. AGC Biologics
  • 11.2.10. Charles River Laboratories